Cáncer de pulmón no microcítico

At diagnosis, more than 50% present with locally advanced or metastatic disease, with a survival rate of 15% at 5 years. Non-small cell lung cancer (NSCLC) is a category that differs in terms of clinical course and prognosis and, therefore, offers different possible treatment options, based on a combination of surgery, chemotherapy and radiotherapy. In recent years, the identification of oncogenic molecular targets has made it possible to develop personalised treatments.